文献类型：期刊文献

中文题名：中医药调控NLRP3炎症小体治疗糖尿病肾病的研究进展

英文题名：Chinese Medicine Regulates NLRP3 Inflammasomes to Treat Diabetic Nephropathy:A Review

作者：赵哲[1];白敏[1];靳玉秋[1];田萌媛[1];陈光顺[1];刘臻华[1]

第一作者：赵哲

机构：[1]甘肃中医药大学,兰州730000

第一机构：甘肃中医药大学

年份：2023

卷号：29

期号：23

起止页码：197

中文期刊名：中国实验方剂学杂志

外文期刊名：Chinese Journal of Experimental Traditional Medical Formulae

收录：CSTPCD;;北大核心:【北大核心2020】；CSCD:【CSCD2023_2024】；

基金：国家自然科学基金地区科学基金项目(82160865);甘肃省优秀研究生“创新之星”基金项目(2022CXZX-769)。

语种：中文

中文关键词：中医药;糖尿病肾病;NOD样受体蛋白3(NLRP3)炎症小体;焦亡;自噬;肾纤维化

外文关键词：Chinese medicine;diabetic nephropathy;NLRP3 inflammasome;pyroptosis;autophagy;renal fibrosis

摘要：糖尿病肾病(DN)是慢性肾脏病(CKD)主要病因,加重了终末期肾脏病(ESRD)的患病率,严重威胁人类健康。DN病理机制十分复杂,其中炎症反应是糖尿病肾病级联损伤过程中的关键病理环节。因此,针对糖尿病肾病炎症反应的治疗有利于缓解DN的疾病进展。NOD样受体蛋白3(NLRP3)是一种经典的蛋白酶体,其作为先天免疫反应的诱导剂,NLRP3炎症小体被激活后产生和释放炎症介质,触发细胞焦亡和自噬失控,介导促肾纤维化的应激信号,参与DN肾脏的发生与发展。NLRP3炎症小体作为诱导炎症反应的核心位点广泛参与了DN疾病进程,可能是DN疾病进展的新靶点。中药单体及复方在糖尿病肾病的防治中起到越来越重要的作用,最新研究发现中医药有效防治DN与调控NLRP3炎症小体激活关系密切。从NLRP3炎症小体角度探究中医药治疗DN发生发展的作用机制的研究较多,但尚缺乏系统综述。该文通过分析汇总近年来国内外文献,从NLRP3炎症小体组装与激活,在糖尿病肾病的作用机制及中医药通过相关途径调控NLRP3炎症小体防治DN方面进行综述,为中医药对NLRP3炎症小体调控研究提供参考,以期为防治DN提供新靶点和新策略。
Diabetic nephropathy(DN),a major cause of chronic kidney disease(CKD),aggravates the prevalence of end-stage renal disease(ESRD)and threatens human health.The pathogenesis of DN is complex,in which inflammation is a key pathological link in the cascade injury.Therefore,the treatment targeting inflammation helps to delay the progression of DN.NOD-like receptor protein 3(NLRP3),a classical proteasome,acts as an inducer of innate immune responses.The activated NLRP3 inflammasomes produce and release inflammatory mediators to trigger pyroptosis and uncontrolled autophagy and mediate the stress signals promoting renal fibrosis,thus participating in the development and progression of DN.The NLRP3 inflammasome as a core site inducing inflammation is widely involved in DN progression and may be a novel target.The active components and compound prescriptions of Chinese medicines are increasingly applied in the prevention and treatment of DN.The latest studies have discovered that Chinese medicines can treat DN by regulating the activation of NLRP3 inflammasomes.Although studies have been conducted to explore the mechanism of Chinese medicines in the treatment of DN via NLRP3 inflammasome,the systematic review remains to be carried out.This paper reviews the relevant publications in recent years and introduces the research progress from the assembly and activation of NLRP3 inflammasomes,the mechanism of NLRP3 inflammasomes in the treatment of DN,and the regulation of NLRP3 inflammasomes by Chinese medicines for the prevention and treatment of DN,aiming to lay a foundation for the relevant studies and provide new targets and strategies for the prevention and treatment of DN.